Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) trial

MR Gold, PD Lambiase, MF El-Chami, RE Knops… - Circulation, 2021 - Am Heart Assoc
Background: The subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and
effective for sudden cardiac death prevention. However, patients in previous S-ICD studies …

Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study

PD Lambiase, DA Theuns, F Murgatroyd… - European Heart …, 2022 - academic.oup.com
Aims To report 5-year outcomes of EFFORTLESS registry patients with early generation
subcutaneous implantable cardioverter-defibrillator (S-ICD) devices. Methods and results …

Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial

RE Knops, S Pepplinkhuizen… - European heart …, 2022 - academic.oup.com
Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) is developed to
overcome lead-related complications and systemic infections, inherent to transvenous ICD …

Air entrapment as a potential cause of early subcutaneous implantable cardioverter defibrillator malfunction: a systematic review of the literature

H Ali, P Lupo, S Foresti, G De Ambroggi, C De Lucia… - Europace, 2022 - academic.oup.com
Aims Air entrapment (AE) has been reported as a potential cause of early inappropriate
shocks (ISs) following subcutaneous implantable cardioverter defibrillator (S-ICD) …

[HTML][HTML] The subcutaneous ICD: a review of the UNTOUCHED and PRAETORIAN trials

A Karimianpour, L John, MR Gold - Arrhythmia & Electrophysiology …, 2021 - ncbi.nlm.nih.gov
The ICD is an important part of the treatment and prevention of sudden cardiac death in
many high-risk populations. Traditional transvenous ICDs (TV-ICDs) are associated with …

[HTML][HTML] Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable …

MS Lloyd, AJ Brisben, VY Reddy… - Heart rhythm O2, 2023 - Elsevier
Background The subcutaneous implantable cardioverter-defibrillator (S-ICD) has
demonstrated safety and efficacy for the treatment of malignant ventricular arrhythmias …

Infection in patients with subcutaneous implantable cardioverter-defibrillator: Results of the S-ICD Post Approval Study

MR Gold, JD Aasbo, R Weiss, MC Burke, MJ Gleva… - Heart Rhythm, 2022 - Elsevier
Background Early subcutaneous implantable cardioverter-defibrillator (S-ICD) studies
included atypical cohorts of patients who were younger with fewer comorbidities. Recent S …

Right ventricular function is a predictor for sustained ventricular tachycardia requiring anti-tachycardic pacing in arrhythmogenic ventricular cardiomyopathy: insight …

S Honarbakhsh, A Protonotarios, C Monkhouse… - Europace, 2023 - academic.oup.com
Aims Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients develop ventricular
arrhythmias (VAs) responsive to anti-tachycardia pacing (ATP). However, VA episodes have …

Pre-implant predictors of inappropriate shocks with the third-generation subcutaneous implantable cardioverter defibrillator

M Ben Kilani, P Jacon, N Badenco, C Marquie… - Europace, 2022 - academic.oup.com
Aims Despite recent improvements, inappropriate shocks emitted by implanted
subcutaneous implantable cardioverter defibrillators (S-ICDs) remain a challenge in 'real …

Intermuscular technique for implantation of the subcutaneous implantable defibrillator: a propensity-matched case–control study

GL Botto, M Ziacchi, G Nigro, A D'Onofrio… - Europace, 2023 - academic.oup.com
Aims A previous randomized study demonstrated that the subcutaneous implantable
cardioverter defibrillator (S-ICD) was noninferior to transvenous ICD with respect to device …